For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the introduction of this treatment and Tafamidis meglumine represents a genuine breakthrough . These novel therapies preserve the transthyretin protein, halting its harmful build-up and lessening the severity of the disease . Individuals are now experie